Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Arginase 1 Deficiency

Tundra lists 3 Arginase 1 Deficiency clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts. Through partnerships with patient advocacy organizations and researchers worldwide, CoRDS helps connect rare disease communities with research opportunities while advancing knowledge across more than 7,000 rare diseases. Participation is free of charge.

Gender: All

Updated: 2026-10-28

1 state

Rare Disorders
Undiagnosed Disorders
Disorders of Unknown Prevalence
+351
RECRUITING

NCT07773246

Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD

Phase 1/2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.

Gender: All

Ages: 18 Years - 65 Years

Updated: 2026-10-08

1 state

Urea Cycle Disorders, Inborn
Urea Cycle Disorders
Ornithine Transcarbamylase (OTC) Deficiency
+8
COMPLETED

NCT06582524

Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

This is an open-label, multicentre study to evaluate the safety, PK, and activity (PD) of weekly subcutaneous (SC) administration of pegzilarginase in subjects with ARG1-D who are \< 24 months of age. The study consists of a screening period of up to 4 weeks, a subsequent 12-week treatment period, and a safety follow-up period of 8 weeks.

Gender: All

Ages: 1 Day - 24 Months

Updated: 2026-05-22

Arginase 1 Deficiency